Monomethyl fumarate
- Generic Name
- Monomethyl fumarate
- Brand Names
- Bafiertam
- Drug Type
- Small Molecule
- Chemical Formula
- C5H6O4
- CAS Number
- 2756-87-8
- Unique Ingredient Identifier
- 45IUB1PX8R
- Associated Conditions
- -
- Associated Therapies
- -
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06279494
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- ITB-Med LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06019507
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Huddinge, Sweden
Observational Study of Persistence on Bafiertam Treatment In Routine Clinical Practice
- Conditions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Banner Life Sciences LLC
- Target Recruit Count
- 100
- Registration Number
- NCT05978531
- Locations
- 🇵🇷
Caribbean Center for Clinical Research, Guaynabo, Puerto Rico
🇺🇸Regina Berkovich, MD, PhD Inc., West Hollywood, California, United States
🇺🇸Arizona Neuroscience Research, LLC, Phoenix, Arizona, United States
Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Target Recruit Count
- 24
- Registration Number
- NCT05951517
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Use of Baricitenib to Maintain of Remission
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 80
- Registration Number
- NCT05686746
- Locations
- 🇪🇬
Manal Hassanien, Assiut, Yes, Egypt
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT05627557
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
KidneyCare Immuno-optimization in Renal Allografts (KIRA)
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- CareDx
- Registration Number
- NCT05423496
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05202145
- Locations
- 🇺🇸
Clinical Study Site, Tempe, Arizona, United States
Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate
- Conditions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Banner Life Sciences LLC
- Registration Number
- NCT04925778
A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 271
- Registration Number
- NCT04221477
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇩🇪Universitaetsmedizin Johannes Gutenberg; Rheumatologie, Mainz, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.